Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Healthcare Global IPO is a book build issue of ₹649.64 crores. The issue is a combination of fresh issue of 1.16 crore shares aggregating to ₹252.88 crores and offer for sale of 1.82 crore shares aggregating to ₹396.76 crores.
Healthcare Global IPO bidding started from Mar 16, 2016 and ended on Mar 18, 2016. The shares got listed on BSE, NSE on Mar 30, 2016.
Healthcare Global IPO price band is set at ₹218.00 per share . The lot size for an application is 65. The minimum amount of investment required by an retail is ₹13,325 (65 shares). The lot size investment for sNII is 15 lots (975 shares), amounting to ₹2,12,550, and for bNII, it is 71 lots (4,615 shares), amounting to ₹10,06,070.
Edelweiss Financial Services Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.
Refer to Healthcare Global IPO RHP for detailed Information.
| IPO Date | March 16, 2016 to March 18, 2016 |
| Listing Date | March 30, 2016 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹205 to ₹218 per share |
| Issue Price Final | ₹218 per share |
| Lot Size | 65 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 2,98,00,000 shares (aggregating up to ₹649.64 Cr) |
| Fresh Issue | 1,16,00,000 shares (aggregating up to ₹252.88 Cr) |
| Offer for Sale | 1,82,00,000 shares of ₹10 (aggregating up to ₹396.76 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 7,34,75,986 shares |
| Share Holding Post Issue | 8,50,75,986 shares |
Healthcare Global IPO offers total 2,98,00,000 shares. Out of which 2,23,50,000 (75.00%) allocated to QIB, 89,40,000 (30.00%) allocated to QIB, 44,70,000 (15.00%) allocated to NII, 29,80,000 (10.00%) allocated to RII and 1,34,10,000 (45.00%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 2,23,50,000 (75.00%) | NA |
| − Anchor Investor Shares Offered | 1,34,10,000 (45.00%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 89,40,000 (30.00%) | NA |
| NII (HNI) Shares Offered | 44,70,000 (15.00%) | NA |
| Retail Shares Offered | 29,80,000 (10.00%) | 45,846 |
| Total Shares Offered | 2,98,00,000 (100.00%) |
Healthcare Global IPO opens on March 16, 2016, and closes on March 18, 2016.
| IPO Open Date | Wed, Mar 16, 2016 |
| IPO Close Date | Fri, Mar 18, 2016 |
| Tentative Listing Date | Wed, Mar 30, 2016 |
| Cut-off time for UPI mandate confirmation | 5 PM on Fri, Mar 18, 2016 |
Investors can bid for a minimum of 65 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 65 | ₹14,170 |
| Retail (Max) | 14 | 910 | ₹1,98,380 |
| S-HNI (Min) | 15 | 975 | ₹2,12,550 |
| S-HNI (Max) | 70 | 4,550 | ₹9,91,900 |
| B-HNI (Min) | 71 | 4,615 | ₹10,06,070 |
Healthcare Global Enterprises Ltd (HCG) is Bangalore India based provider of speciality healthcare in India focused on cancer and fertility.
HCG operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed. HCG also operates fertility centres under the 'Milann' brand.
As of December 31, 2015, HCG network consisted of 14 comprehensive cancer centres, including centre of excellence in Bengaluru, three freestanding diagnostic centres and one day care chemotherapy centre across India.
HCG acquired 50.10% equity in BACC Healthcare in 2013 which operates fertility centres under the Milann brand, through itself and its wholly-owned subsidiary, DKR Healthcare. HCG now operate four Milann fertility centres in Bengaluru. BACC Healthcare is led by a team of qualified and experienced fertility specialists. Its founder, Dr. Kamini Rao has a successful track record of over 25 years of providing fertility treatments. Milann fertility centres provide comprehensive reproductive medicine services, including assisted reproduction, gynaecological endoscopy and fertility preservation; and follow a multidisciplinary and technology-focused approach to diagnosis and treatment.
Under Triesta brand, HCG provide clinical reference laboratory services in India with a specialisation in oncology, including molecular diagnostic services and genomic testing. Triesta central reference laboratory is located in centre of excellence in Bengaluru.
Strengths of the Company:
1. Largest provider of cancer care in India with a proven track record
2. High quality cancer care provided at a competitive price
3. Entry into high potential fertility business
4. Strong management team with successful track record
5. Highly skilled specialist physicians
6. 'hub and spoke' business model and partnership arrangements
|
Particulars |
For the year/period ended (in Rs. Million) | ||||
| 31-Mar-15 | 31-Mar-14 | 31-Mar-13 | 31-Mar-12 | 31-Mar-11 | |
| Total Liabilities | 6,895.42 | 6,138.21 | 6,436.40 | 4,362.63 | 3,203.63 |
| Total Assets | 6,895.42 | 6,138.21 | 6,436.40 | 4,362.63 | 3,203.63 |
| Total Revenue | 4,244.41 | 3,525.94 | 2,939.52 | 2,051.67 | 1,601.43 |
| Profit After Tax (PAT) | (23.66) | (394.98) | (71.58) | (40.02) | 34.40 |
The Company Healthcare Global IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | Purchase of medical equipment | 42.21 |
| 2 | Investment in IT software, services and hardware | 30.19 |
| 3 | Pre-payment of debt | 147.05 |
| 4 | General corporate purposes | 19.77 |
[Dilip Davda] <p>Although the company’s performance has been in negative zone, unique model of Cancer and Fertility treatment under HCG and Milann brands are expected to generate positive earnings in next two to three years. Long term investors may consider investment for adding value on their investment.</p> Read detail review...
| Listing Date | March 30, 2016 |
| BSE Script Code | 539787 |
| NSE Symbol | HCG |
| ISIN | INE075I01017 |
| Final Issue Price | ₹218 per share |
| BSE Listing Group | B |
Healthcare Global Enterprises Ltd.
HCG Tower, No. 8, P Kalinga Rao Road,
Sampangi Rama Nagar,
Bengaluru 560 027
Bengaluru, Karnataka
Phone: +91 80 4660 7700
Email: investors@hcgoncology.com
Website: http://www.hcgel.com
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: einward.ris@karvy.com
Website: https://ipostatus.kfintech.com/
Lead Manager Reports
Healthcare Global IPO is a main-board IPO of 2,98,00,000 equity shares of the face value of ₹10 aggregating up to ₹649.64 Crores. The issue is priced at ₹218 per share. The minimum order quantity is 65.
The IPO opens on March 16, 2016, and closes on March 18, 2016.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Healthcare Global IPO using UPI as a payment gateway. Zerodha customers can apply in Healthcare Global IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Healthcare Global IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Healthcare Global IPO opens on March 16, 2016 and closes on March 18, 2016.
Healthcare Global IPO lot size is 65, and the minimum amount required for application is ₹14,170.
You can apply in Healthcare Global IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Healthcare Global IPO will be done on [.], and the allotted shares will be credited to your demat account by [.]. Check the Healthcare Global IPO allotment status.
The Healthcare Global IPO listing date is on Wednesday, March 30, 2016.
Useful Articles
RHP